TP53 and carcinoma: Moreover, we have to keep in mind that some G3 EEC or ambiguous carcinomas with a mutator phenotype (either POLEmut or MMRd) can acquire a TP53 mutation later in the tumoral course, developing a subclonal TP53 mutation that may result in heterogenous p53 expression, with a combination of normal wild-type and abnormal patterns (overexpression and/or ‘null’ phenotype and/or cytoplasmic staining).